10219-10-0

Basic information

• Product Name: Acetamide, N-(4-chlorophenyl)-N-methyl-
• CAS NO: 10219-10-0
• Molecular Formula: C9H10ClNO
• Molecular Weight: 183.637
• Mol File: 10219-10-0.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Acetamide, N-(4-chlorophenyl)-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-(4-chlorophenyl)-N-methyl-(10219-10-0)
• EPA Substance Registry System: Acetamide, N-(4-chlorophenyl)-N-methyl-(10219-10-0)

Safety Data

• Hazardous Substances Data: 10219-10-0(Hazardous Substances Data)

Upstream product

• 932-96-7 N-methyl(p-chloroaniline) 
• 539-03-7 N-(4-chlorophenyl)acetamide 
• 3847-19-6 2-acetoxypyridine 
• 698-69-1 4-chloro-N,N-dimethylaniline 
• 108-24-7 acetic anhydride 
• 106-47-8 4-chloro-aniline 
• 579-10-2 N-acetyl-N-methylaniline 
• 373-68-2 tetramethylammonium fluoride 
• 80-43-3 bis(1-methyl-1-phenylethyl)peroxide 
• 74-88-4 methyl iodide 
• 876-00-6 p-chloro-N,N-dimethylaniline-N-oxide 

Downstream Products

• 1404509-20-1 N-(4-chlorophenyl)-N-methylethenesulfonamide 
• 932-96-7 N-methyl(p-chloroaniline) 
• 13519-85-2 4-chloro-N-ethyl-N-methylaniline 
• 26961-99-9 4-(N-acetyl-N-methylamino)benzoic acid 
• 1173504-78-3 N-(4-chloro-2-((triisopropylsilyl)ethynyl)phenyl)-N-methylacetamide 

Relevant articles and documents

-

-

Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy

Hormone therapy targeting estrogen receptors is widely used clinically for the treatment of breast cancer, such as tamoxifen, but most of them are partial agonists, which can cause serious side effects after long-term use. The use of selective estrogen receptor down-regulators (SERDs) may be an effective alternative to breast cancer therapy by directly degrading ERα protein to shut down ERα signaling. However, the solely clinically used SERD fulvestrant, is low orally bioavailable and requires intravenous injection, which severely limits its clinical application. On the other hand, double- or multi-target conjugates, which are able to synergize antitumor activity by different pathways, thus may enhance therapeutic effect in comparison with single targeted therapy. In this study, we designed and synthesized a series of novel dual-functional conjugates targeting both ERα degradation and histone deacetylase inhibiton by combining a privileged SERD skeleton 7-oxabicyclo[2.2.1]heptane sulfonamide (OBHSA) with a histone deacetylase inhibitor side chain. We found that substituents on both the sulfonamide nitrogen and phenyl group of OBHSA unit had significant effect on biological activities. Among them, conjugate 16i with N-methyl and naphthyl groups exhibited potent antiproliferative activity against MCF-7 cells, and excellent ERα degradation activity and HDACs inhibitory ability. A further molecular docking study indicated the interaction patterns of these conjugates with ERα, which may provide guidance to design novel SERDs or PROTAC-like SERDs for breast cancer therapy.

Selective Methylation of Amides, N-Heterocycles, Thiols, and Alcohols with Tetramethylammonium Fluoride

We herein disclose the use of tetramethylammonium fluoride (TMAF) as a direct and selective methylating agent of a variety of amides, indoles, pyrroles, imidazoles, alcohols, and thiols. The method is characterized by operational simplicity, wide scope, and ease of purification. Our computational studies suggest a concerted methylation-deprotonation as the preferred reaction pathway.

Room temperature C(sp2)-H oxidative chlorination: Via photoredox catalysis

Photoredox catalysis has been developed to achieve oxidative C-H chlorination of aromatic compounds using NaCl as the chlorine source and Na2S2O8 as the oxidant. The reactions occur at room temperature and exhibit exclusive selectivity for C(sp2)-H bonds over C(sp3)-H bonds. The method has been used for the chlorination of a diverse set of substrates, including the expedited synthesis of key intermediates to bioactive compounds and a drug.